News

San Diego, Calif. and Jerusalem, May 17, 2012 – Ambit Biosciences and Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) (“Teva”) today announced the clearance of an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) for CEP-32496, a novel BRAF (V600E) kinase inhibitor.

CHAPEL HILL, N.C.- February 3, 2012 - Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced the pricing of its initial public offering of 8,400,000 shares of its common stock at a price to the public of $6.00 per share. Cempra also has granted the underwriters a 30-day option to purchase up to an additional 1,260,000 shares to cover over-allotments, if any.

Tokyo and San Diego, Calif., December 1, 2011 - December 1, 2011 Astellas Pharma Inc. (Tokyo: 4503, Astellas) and Ambit Biosciences Corporation (Ambit) today announced that four poster presentations and four oral presentations highlighting the findings from multiple preclinical and clinical studies evaluating quizartinib (formerly known as AC220), a potent and selective FLT3 inhibitor intended for the treatment of acute myeloid leukemia (AML), will be presented at the American Society of Hematology (ASH) 53rd Annual Meeting, December 10-13, 2011, at the San Diego Convention Center in San Diego, Calif.

SAN DIEGO, Nov. 16, 2011 – Ambit Biosciences Inc. today announced the appointment of Michael A. Martino as President, Chief Executive Officer and member of the Board of Directors. Martino brings to Ambit a nearly 30-year track record in leading privately held and publicly traded life sciences companies through late-stage clinical development, fundraising, commercial and business development activities, including new product launches and mergers and acquisitions. He replaces Alan Lewis, Ph.D., who announced his departure earlier this year and recently left the company after supporting the transition to Martino’s appointment.

PLEASANTON, Calif.--(BUSINESS WIRE)-- ZELTIQ® Aesthetics, Inc. (NASDAQ:ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced the pricing of its initial public offering of 7,000,000 shares of its common stock at a price of $13.00 per share. The shares are expected to begin trading on October 19, 2011 on The NASDAQ Global Select Market under the ticker symbol "ZLTQ." ZELTIQ is offering 6,693,000 shares and selling stockholders are offering the remaining 307,000 shares. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,050,000 shares of common stock from ZELTIQ to cover over-allotments, if any.

Lexington, MA, August 10, 2011 – T2 Biosystems® announced today that it has closed a $23 million series D financing. The round was led by new investor Aisling Capital, LLC, which was joined by existing investors Flagship Ventures, Polaris Venture Partners, Flybridge Capital Partners, Physic Ventures, Partners Healthcare, Arcus Ventures, RA Capital, Camros Capital and WS Investments. In conjunction with the financing, Josh Bilenker, M.D., Principal at Aisling Capital, will join T2 Biosystems’s Board of Directors. The proceeds from this round will support ongoing development and clinical trials as the Company moves towards regulatory approval and commercialization of their T2MR diagnostic technology, as well as enable expansion of the Company’s partnering program. T2 Biosystems’s lead product is a rapid detection assay for Candida, a fungal pathogen known to cause blood stream infections and sepsis.

London, June 13, 2011 – Ambit Biosciences Corporation and Astellas Pharma Inc. announced today results from a planned interim analysis in an ongoing Phase 2 study evaluating AC220, a potent and selective FLT3 inhibitor. The study is evaluating AC220 as an oral, once-a-day, monotherapy treatment in acute myeloid leukemia (AML) in 240 patients with FLT3-ITD activating mutations who have relapsed or are refractory to other treatments, including chemotherapy and hematopoietic stem cell transplant (HSCT). The data from this analysis was presented in an oral session at the 16th Annual Congress of the European Hematology Association (EHA) in London.